132 related articles for article (PubMed ID: 38698650)
1. Effect of semaglutide 2.4 mg on physical functioning and weight- and health-related quality of life in adults with overweight or obesity: Patient-reported outcomes from the STEP 1-4 trials.
Rubino D; Bjorner JB; Rathor N; Sharma AM; von Huth Smith L; Wharton S; Wadden T; Zeuthen N; Kolotkin RL
Diabetes Obes Metab; 2024 Jul; 26(7):2945-2955. PubMed ID: 38698650
[TBL] [Abstract][Full Text] [Related]
2. Effect of once-weekly subcutaneous semaglutide 2.4 mg on weight- and health-related quality of life in an East Asian population: Patient-reported outcomes from the STEP 6 trial.
Kolotkin RL; Jeppesen OK; Baker-Knight J; Lee SY; Tokita A; Kadowaki T
Clin Obes; 2023 Aug; 13(4):e12589. PubMed ID: 36905345
[TBL] [Abstract][Full Text] [Related]
3. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial.
Rubino D; Abrahamsson N; Davies M; Hesse D; Greenway FL; Jensen C; Lingvay I; Mosenzon O; Rosenstock J; Rubio MA; Rudofsky G; Tadayon S; Wadden TA; Dicker D;
JAMA; 2021 Apr; 325(14):1414-1425. PubMed ID: 33755728
[TBL] [Abstract][Full Text] [Related]
4. Exploring the wider benefits of semaglutide treatment in obesity: insight from the STEP program.
O'Neil PM; Rubino DM
Postgrad Med; 2022 Jan; 134(sup1):28-36. PubMed ID: 36691307
[TBL] [Abstract][Full Text] [Related]
5. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial.
Wadden TA; Bailey TS; Billings LK; Davies M; Frias JP; Koroleva A; Lingvay I; O'Neil PM; Rubino DM; Skovgaard D; Wallenstein SOR; Garvey WT;
JAMA; 2021 Apr; 325(14):1403-1413. PubMed ID: 33625476
[TBL] [Abstract][Full Text] [Related]
6. Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial.
Davies M; Færch L; Jeppesen OK; Pakseresht A; Pedersen SD; Perreault L; Rosenstock J; Shimomura I; Viljoen A; Wadden TA; Lingvay I;
Lancet; 2021 Mar; 397(10278):971-984. PubMed ID: 33667417
[TBL] [Abstract][Full Text] [Related]
7. Validation of a new measure of quality of life in obesity trials: Impact of Weight on Quality of Life-Lite Clinical Trials Version.
Kolotkin RL; Williams VSL; Ervin CM; Williams N; Meincke HH; Qin S; von Huth Smith L; Fehnel SE
Clin Obes; 2019 Jun; 9(3):e12310. PubMed ID: 30993900
[TBL] [Abstract][Full Text] [Related]
8. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial.
Rubino DM; Greenway FL; Khalid U; O'Neil PM; Rosenstock J; Sørrig R; Wadden TA; Wizert A; Garvey WT;
JAMA; 2022 Jan; 327(2):138-150. PubMed ID: 35015037
[TBL] [Abstract][Full Text] [Related]
9. Improvements in health-related quality of life with liraglutide 3.0 mg compared with placebo in weight management.
Kolotkin RL; Fujioka K; Wolden ML; Brett JH; Bjorner JB
Clin Obes; 2016 Aug; 6(4):233-42. PubMed ID: 27198973
[TBL] [Abstract][Full Text] [Related]
10. Improvements in health-related quality of life over 3 years with liraglutide 3.0 mg compared with placebo in participants with overweight or obesity.
Kolotkin RL; Gabriel Smolarz B; Meincke HH; Fujioka K
Clin Obes; 2018 Feb; 8(1):1-10. PubMed ID: 29045079
[TBL] [Abstract][Full Text] [Related]
11. Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial.
Kadowaki T; Isendahl J; Khalid U; Lee SY; Nishida T; Ogawa W; Tobe K; Yamauchi T; Lim S;
Lancet Diabetes Endocrinol; 2022 Mar; 10(3):193-206. PubMed ID: 35131037
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of once weekly semaglutide 2·4 mg for weight management in a predominantly east Asian population with overweight or obesity (STEP 7): a double-blind, multicentre, randomised controlled trial.
Mu Y; Bao X; Eliaschewitz FG; Hansen MR; Kim BT; Koroleva A; Ma RCW; Yang T; Zu N; Liu M;
Lancet Diabetes Endocrinol; 2024 Mar; 12(3):184-195. PubMed ID: 38330988
[TBL] [Abstract][Full Text] [Related]
13. The improved health utility of once-weekly subcutaneous semaglutide 2.4 mg compared with placebo in the STEP 1-4 obesity trials.
Bjorner JB; Larsen S; Lübker C; Holst-Hansen T
Diabetes Obes Metab; 2023 Aug; 25(8):2142-2150. PubMed ID: 37055712
[TBL] [Abstract][Full Text] [Related]
14. Health-related quality of life in two randomized controlled trials of phentermine/topiramate for obesity: What mediates improvement?
Kolotkin RL; Gadde KM; Peterson CA; Crosby RD
Qual Life Res; 2016 May; 25(5):1237-44. PubMed ID: 26446094
[TBL] [Abstract][Full Text] [Related]
15. Confirmatory psychometric evaluations of the Impact of Weight on Quality of Life-Lite Clinical Trials Version (IWQOL-Lite-CT).
Kolotkin RL; Williams VSL; von Huth Smith L; Meincke HH; Qin S; Williams N; Fehnel SE
Clin Obes; 2021 Oct; 11(5):e12477. PubMed ID: 34296522
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial.
O'Neil PM; Birkenfeld AL; McGowan B; Mosenzon O; Pedersen SD; Wharton S; Carson CG; Jepsen CH; Kabisch M; Wilding JPH
Lancet; 2018 Aug; 392(10148):637-649. PubMed ID: 30122305
[TBL] [Abstract][Full Text] [Related]
17. Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial.
Knop FK; Aroda VR; do Vale RD; Holst-Hansen T; Laursen PN; Rosenstock J; Rubino DM; Garvey WT;
Lancet; 2023 Aug; 402(10403):705-719. PubMed ID: 37385278
[TBL] [Abstract][Full Text] [Related]
18. Once-Weekly Semaglutide in Adults with Overweight or Obesity.
Wilding JPH; Batterham RL; Calanna S; Davies M; Van Gaal LF; Lingvay I; McGowan BM; Rosenstock J; Tran MTD; Wadden TA; Wharton S; Yokote K; Zeuthen N; Kushner RF;
N Engl J Med; 2021 Mar; 384(11):989-1002. PubMed ID: 33567185
[TBL] [Abstract][Full Text] [Related]
19. Clinical review of subcutaneous semaglutide for obesity.
Phillips A; Clements JN
J Clin Pharm Ther; 2022 Feb; 47(2):184-193. PubMed ID: 34964141
[TBL] [Abstract][Full Text] [Related]
20. Changes in Glucose Metabolism and Glycemic Status With Once-Weekly Subcutaneous Semaglutide 2.4 mg Among Participants With Prediabetes in the STEP Program.
Perreault L; Davies M; Frias JP; Laursen PN; Lingvay I; Machineni S; Varbo A; Wilding JPH; Wallenstein SOR; le Roux CW
Diabetes Care; 2022 Oct; 45(10):2396-2405. PubMed ID: 35724304
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
